Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.45 |
| ▸ | DRD2 | P14416 | 12/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662643 | 1.00 | DRD3 (0.45) | DRD3KCNH2DRD2CYP2C19ADRA1D | |
| SCHEMBL13314202 | 1.00 | DRD3 (0.45) | DRD3KCNH2DRD2CYP2C19ADRA1D | |
| SCHEMBL15196038 | 1.00 | DRD3 (0.45) | DRD3KCNH2DRD2CYP2C19ADRA1D | |
| SCHEMBL10120660 | 0.89 | DRD3 (0.46) | DRD3KCNH2DRD2 | |
| SCHEMBL2745493 | 0.89 | DRD3 (0.46) | DRD3KCNH2DRD2 | |
| SCHEMBL13882099 | 0.89 | DRD3 (0.46) | DRD3KCNH2DRD2 | |
| SCHEMBL10107813 | 0.89 | DRD3 (0.46) | DRD3KCNH2DRD2 | |
| SCHEMBL13349019 | 0.88 | DRD2 (0.49) | DRD3KCNH2DRD2CYP2C19ADRA1D | |
| SCHEMBL13314297 | 0.88 | DRD2 (0.49) | DRD3KCNH2DRD2CYP2C19ADRA1D | |
| SCHEMBL3564326 | 0.88 | DRD2 (0.49) | DRD3KCNH2DRD2CYP2C19ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007750-B1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | DRD3 524/4885KCNH2 66/4885DRD2 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.